We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
-0.71%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$168M
AUM Growth
-$5.13M
Cap. Flow
+$3.65M
Cap. Flow %
2.17%
Top 10 Hldgs %
74.37%
Holding
57
New
9
Increased
8
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$3.3M
2
CGEM icon
Cullinan Oncology
CGEM
+$2.44M
3
NKTR icon
Nektar Therapeutics
NKTR
+$1.91M
4
ELTX icon
Elicio Therapeutics
ELTX
+$1.17M
5
ALKS icon
Alkermes
ALKS
+$716K

Top Sells

Rank Stock Value
1
AWH
Aspira Women's Health Inc. Common Stock
AWH
+$5.4M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.97M
3
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$763K
4
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$384K
5
STOK icon
Stoke Therapeutics
STOK
+$285K

Sector Composition

Rank Sector Weight
1 Healthcare 96.34%
2 Energy 1.49%
3 Consumer Staples 0.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YTEN
51
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$238K 0.14%
790
– –
BCRX icon
52
BioCryst Pharmaceuticals
BCRX
$2.37B
$203K 0.12%
20,000
– –
TXMD icon
53
TherapeuticsMD
TXMD
$23.8M
$134K 0.08%
+2,000
New +$157K
CNCE
54
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$100K 0.06%
+20,000
New +$162K
ODT
55
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
– –
-20,000
Closed -$384K
OXFD
56
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-170,303
Closed -$2.97M
BMY.RT
57
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
– –
-1,105,313
Closed -$763K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return
AF
Align Financial Hermantown, Minnesota $176M AUM
OA
Oceanside Advisors Mount Pleasant, South Carolina $175M AUM 17.96% 1-Year Est. Return

Birchview Capital's Q1 2021 Portfolio in Review

As of Q1 2021, Birchview Capital held 57 positions worth $168M, down 3% from $174M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Birchview Capital's Q1 2021 filing shows 9 new, 8 increased, 4 reduced and 3 closed positions. Its largest new stake was Cullinan Oncology: 60,114 shares worth $2.5M. The largest sale was Aspira Women's Health Inc. Common Stock, an estimated $5.4M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2021 buy was Cullinan Oncology: 60,114 shares worth $2.5M.
  • Birchview Capital added most to Acadia Pharmaceuticals in Q1 2021, an estimated $3.3M increase.
  • Birchview Capital's biggest Q1 2021 reduction was Aspira Women's Health Inc. Common Stock, cutting an estimated $5.4M.
  • Birchview Capital fully exited Oxford Immunotec Global PLC Ordinary Shares in Q1 2021, selling an estimated $2.97M.
  • Birchview Capital's ten largest holdings make up 74% of its $168M portfolio in Q1 2021.
  • Birchview Capital opened 9 new positions and closed 3 in Q1 2021.
  • Birchview Capital's portfolio value fell 3% quarter-over-quarter to $168M.

Based on Birchview Capital's 13F filing for Q1 2021, filed 14 May 2021.